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Two oral fluoropyrimidine therapies have been introduced for metastatic colorectal cancer. One is a 5-fluorouracil pro-drug,
capecitabine; the other is a combination of tegafur and uracil administered together with leucovorin. The purpose of this study was to
compare the clinical effectiveness and cost-effectiveness of these oral therapies against standard intravenous 5-fluorouracil regimens.
A systematic literature review was conducted to assess the clinical effectiveness of the therapies and costs were calculated from the
UK National Health Service perspective for drug acquisition, drug administration, and the treatment of adverse events. A cost-
minimisation analysis was used; this assumes that the treatments are of equal efficacy, although direct randomised controlled trial
(RCT) comparisons of the oral therapies with infusional 5-fluorouracil schedules were not available. The cost-minimisation analysis
showed that treatment costs for a 12-week course of capecitabine (d2132) and tegafur with uracil (d3385) were lower than costs for
the intravenous Mayo regimen (d3593) and infusional regimens on the de Gramont (d6255) and Modified de Gramont (d3485)
schedules over the same treatment period. Oral therapies result in lower costs to the health service than intravenous therapies.
Further research is needed to determine the relative clinical effectiveness of oral therapies vs infusional regimens.
British Journal of Cancer (2006) 95, 27–34. doi:10.1038/sj.bjc.6603215 www.bjcancer.com
& 2006 Cancer Research UK
Keywords: cost-effectiveness; chemotherapy; colorectal cancer; capecitabine; tegafur
                                             
Colorectal cancer is the second most common cause of cancer
death in the United Kingdom. The incidence rises with age, being
rare in people under 40 years of age, and 40% of patients are over
70 years old (Rougier and Mitry, 2003). Approximately 20% of
patients with colorectal cancer present with advanced disease
(Young and Rea, 2000), that is, disease which is already beyond
the scope of curative resection, and a further 20–30% go on to
develop advanced disease at a later date. Thus, around 45% of
patients diagnosed with this disease eventually die of it. The
median survival of patients with inoperable colorectal cancer
treated without anticancer therapy is around 6–9 months. The
main aims of treatment for patients with inoperable colorectal
cancer are to relieve symptoms, prolong survival, and improve
quality of life.
In the UK, palliative chemotherapy is offered to an increasing
number of patients with metastatic colorectal disease (Cunningham
et al, 2002). Various regimens are used in the treatment of
metastatic colorectal cancer. During the 1980s and 1990s, standard
first-line chemotherapy was intravenous 5-FU with the biomodu-
lator leucovorin (5-FU/LV), with practice in the USA favouring
bolus administration schedules (Poon et al, 1989) while in Europe
and the UK the less toxic but more complex protracted infusional
schedules were common (De Gramont et al, 1997). After 2000,
many countries moved over to routine first-line combination
therapy, usually involving 5-FU/LV and irinotecan; however, this
approach was not adopted in the UK, where the National Institute
for Clinical Excellence (NICE) continued to recommend single-
agent fluoropyrimidine therapy as the routine first-line treatment
for most patients. The Mayo Clinic regimen (Poon et al, 1989)
combines bolus intravenous 5-FU with the biomodulator leucov-
orin (5-FU/LV), and acts as a comparator in many international
trials of new therapies. The main alternatives to the Mayo bolus
regimen are infusional regimens such as the de Gramont regimen
(de Gramont et al, 1997) and, in the UK, the ‘Modified de
Gramont’ (MdG) regimen (Cheeseman et al, 2002). These
infusional FU/LV regimens are associated with higher response
rates, longer progression-free survival, and less acute toxicity than
the Mayo schedule, but since they have not been shown to be
clearly superior in terms of survival, the choice of regimen may
depend on clinician and patient preference as well as available
resources.
Oral chemotherapeutic agents may be taken at home and require
fewer hospital visits. They may therefore offer advantages over the
bolus and infusional intravenous regimens. Two oral treatments,
capecitabine (Xeloda
s, Roche) and UFT/LV (tegafur with uracil in
combination with leucovorin, marketed as Uftoral
s, Bristol-Myers
Squibb), are licensed for use in the UK. 5-FU is unsuitable for oral
use as it is largely destroyed by catabolism in the gastrointestinal
tract before reaching general circulation. However, capecitabine is
a 5-FU prodrug, activated to 5-FU itself by a three-step metabolic
pathway in normal and tumour tissues. UFT also contains a 5-FU
prodrug, tegafur, along with uracil, which is used to inhibit the
degradation of 5-FU. Received 15 June 2005; revised 11 May 2006; accepted 11 May 2006
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strategies in comparison to standard intravenous chemotherapy
regimens used in the UK and to determine whether oral drugs are
cost-effective in the treatment of metastatic colorectal cancer.
MATERIALS AND METHODS
Evidence on effectiveness
A systematic review of the literature was performed to identify
randomised controlled trials (RCTs) or meta-analyses that
compared capecitabine or tegafur with uracil with 5-FU/LV
regimens as first-line treatment for metastatic colorectal cancer.
An extensive literature search was conducted in electronic
databases (CancerLit, Cocharane Library, Medline, Embase, etc).
‘Population’ search terms (e.g. colorectal, colon, rectum, neoplasm,
carcinoma, adenocarcinoma) were combined with ‘intervention’
terms (e.g. capecitabine, Xeloda, fluoropyrimidine, tegafur, Uftoral).
Details of the literature searches were described previously (Ward
et al, 2003). The reference lists of relevant articles were hand
searched. Trials were assessed for the following outcome measures:
survival rates, progression-free survival, tumour response, and
time to treatment failure.
The relative benefits in terms of survival gain, progression-free
survival gain, adverse effects, and quality of life were established
for the oral drugs through the results of the phase III RCTs found
in the literature search. Due to the paucity of data, only a narrative
synthesis was undertaken.
Comparator
Intravenous 5-FU/LV was chosen as the comparator for the
economic analysis because at the time of the study it was the most
common first-line treatment for metastatic colorectal cancer
currently in use in the UK. Although the Mayo regimen was used
as a comparator in international trials at that time, this was not
universally accepted in the UK. Survey results suggested that the
Mayo, de Gramont and MdG (Cheeseman et al, 2002) regimens
were all widely used in the UK (Summerhayes, 2003). This is
broadly supported by the results of an earlier survey (Seymour
et al, 1997). We therefore chose to compare the oral drugs against
the Mayo regimen and two infusional regimens: the de Gramont
regimen and the MdG regimen.
Resource utilisation data
Resources used in the administration of the oral chemotherapy
and Mayo regimens were taken primarily from the trial protocol
and were validated against published evidence, where available,
and discussion with local clinicians. Resources used for the de
Gramont and MdG regimens were taken from previously published
studies (Iveson et al, 1999; Cheeseman et al, 2002).
Utilisation for each regimen was based on the recommended
doses in patients of average size (1.75m
2) as follows: capecitabine,
four tablets of 500mg and one of 150mg (total 2150mg) twice
daily for 14 days every 3 weeks; UFT, five capsules (500mg tegafur
and 1120mg uracil) plus 90mg oral LV, daily for 28 days every 5
weeks; Mayo regimen, 5-FU 750mg plus d,l-LV 35mg daily for 5
days every 4 weeks; de Gramont regimen, total doses over 48h of
3500mg 5-FU plus 700mg d,l-LV every 2 weeks; MdG regimen,
total doses over 48h of 5600mg 5-FU plus 350mg d,l-LV every 2
weeks.
Patients undergoing oral therapies were assumed to attend one
outpatient appointment each cycle. Patients on the Mayo regimen
were assumed to attend five outpatient visits each cycle. The de
Gramont regimen was developed as outpatient regimen, using
ambulatory pumps; but despite this, for a combination of reasons
including funding mechanisms and poorly developed ambulatory
treatment services, it became common practice in the 1990s for UK
units to admit patients to hospital for each treatment cycle. In
contrast, the MdG regimen is now almost universally given in the
outpatient setting. For the purposes of this analysis we have
therefore included for historical interest the original de Gramont
regimen, given on an inpatient basis, incurring two in-patient days
per cycle. Patients on the MdG regimen, as used currently in the
UK, are assumed to receive it as outpatients, incurring one
outpatient attendance and two community nurse home visits to
disconnect and maintain their infusion lines each cycle plus
additional resource usage associated with line insertion and
infusion pumps (Cheeseman et al, 2002).
Estimates of the costs of management of adverse events took
into account hospitalisations, physician consultations and drug
treatment costs (Ward et al, 2003). For the treatment of adverse
events resource utilisation data for the oral drugs and the Mayo
regimen were taken from published resource use studies
(Ollendorf, 1999; Twelves et al, 2001) and unpublished data from
trials (Roche, 2002), in consultation with UK clinicians. For the de
Gramont and MdG regimens resource utilisation for adverse
events was taken from a previous analysis of colorectal therapies
(Lloyd-Jones et al, 2001). The cost of line complications for
patients on the ambulatory MdG regimen was based on estimates
of the frequency of occurrence and cost of treating complications.
(James R, Mid Kent Oncology Centre, Maidstone, personal
communication, 2002). Complications included re-siting of the
line in 5% of cases. Resource usage estimates were combined with
UK unit costs taken from Netten et al (2001). Given the uncertainty
relating to estimation of adverse event costs, a sensitivity analysis
was examined in which adverse events were excluded and only
drug acquisition and administration costs were considered.
Costs
Costs were calculated from the perspective of the National Health
Service (NHS) in the UK. All costs were adjusted to the year 2002.
Unit costs are reported in Table 1. No discounting has been
applied given that the median overall survival of patients in the
majority of studies in this analysis was around 12 months.
Drug acquisition costs were based on an individual with a body
surface area of 1.75m
2, with allowance for wastage. VAT was
calculated on all drug costs. Unit costs for drugs were based on the
BNF (British National Formulary, 2002), which do not reflect any
bulk purchase discounts that may be negotiated. Discussion with
clinicians indicated that a significant discount is often obtained for
leucovorin within the NHS, although the level of discount may vary
between institutions and over time. The impact of this discount
was considered in sensitivity analysis.
Costs of GP visits and District Nurse visits were taken from
Netten et al (2001). Estimates for the cost of outpatient
appointments were taken from the accounts of a local hospital as
well as published sources (Netten et al, 2001). Given that the
estimates of cost of outpatient appointments were subject to wide
variation, a range of possible costs was tested in sensitivity
analysis. One-off costs included education for patients on oral
therapies, and line insertion and overnight admissions associated
with the MdG regimen (Iveson et al, 1999).
Length of treatment
A previous UK phase III trial showed that stopping chemotherapy
after 3 months in stable or responding patients, then restarting
upon progression, is noninferior to continuing chemotherapy in
terms of survival (Maughan et al, 2003). On this basis, many UK
clinicians offer treatment breaks from 12 weeks, and consequently
treatment duration is highly variable. For the purposes of
economic evaluation, it was assumed that all patients would be
treated for 12 weeks. This assumption may, however, under-
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beyond 12 weeks, and a proportion of patients who stop treatment
at 12 weeks may resume treatment later. A sensitivity analysis was
considered in which total treatment costs were based on median
treatment times from the trials.
Cost analysis
A cost-minimisation analysis was performed for comparisons of
capecitabine and UFT/LV with the Mayo regimen, since the
survival benefits were shown to be statistically equivalent. A cost-
minimisation analysis was also performed for comparisons of
capecitabine and UFT/LV with the infusional regimens. The
infusional de Gramont and MdG regimens produce higher
response rates and progression-free intervals than the Mayo
regimen, but in the only direct comparative trial overall survival
with the de Gramont regimen was not significantly increased
compared with Mayo (de Gramont et al, 1997). In the absence of
direct evidence of a survival advantage for infusional therapy, a
cost-minimisation analysis was therefore considered appropriate.
Sensitivity analysis
A number of assumptions were made in the base case analysis that
could potentially influence the results of the cost effectiveness
analysis. To understand the impact of these assumptions on the
results of the analysis, they were tested in a sensitivity analysis.
Firstly market research conducted by Bristol-Myers Squibb,
supported by feedback from a number of different NHS trusts
contacted by the authors, suggested that hospitals purchased
leucovorin at a substantially discounted price. The impact of
applying the reported average discount of 87% was tested in
sensitivity analysis (Scenario A). Secondly, the estimation of drug
costs was based on the mean dose intensity from the trials, rather
than the doses specified in the Summaries of Product Character-
istics (Scenario B). Thirdly, the impact of estimating total drug
costs based on the median treatment times in the trials, rather than
assuming a 12-week treatment period for all drugs, was considered
(Scenario C). In addition, two scenarios were run to illustrate the
impact of varying assumptions on the cost of outpatient
appointments: in one scenario, outpatient appointments for both
oral and infusional therapies were assumed to incur the same cost
of d109 (Netten et al, 2001) (Scenario D1); in the other scenario,
the outpatient appointments were costed, based on NHS reference
costs, at d86 for an outpatient appointment for oral therapies
(follow-up medical oncology appointment) and d212 for a daycase
appointment for intravenous therapies (medical oncology day-case
appointment) (Scenario D2). Finally, given the substantial
uncertainty surrounding the estimation of adverse event costs, a
scenario was examined in which adverse event costs were excluded
from the calculation of total treatment costs (Scenario E).
RESULTS
Description of included studies
Three studies were identified which provided evidence on the use
of capecitabine. This included two open label phase III RCTs (Hoff
et al, 2001; Van Cutsem et al, 2001) and a study of pooled data
from these two RCTs (Twelves, 2002). These studies compared
treatment with capecitabine and the Mayo regimen. Two open
label phase III RCTs of UFT/LV were identified (Carmichael et al,
2002; Douillard et al, 2002). The Douillard study compared UFT/
LV with the Mayo regimen while the Carmichael study compared
UFT/LV with a modification of the Mayo regimen.
Assessment of effectiveness
Duration of response and overall survival were not found to be
significantly different between capecitabine and 5-FU/LV. Overall
response rates, assessed by the investigator, were significantly
greater in both trials in the capecitabine group. This improved
response rate with capecitabine was confirmed by an independent
Table 1 Unit costs (d2002)
Item Cost (d2002) Source
In-patient day 367 Netten et al (2001)
Outpatient day 111 Netten et al (2001)
Outpatient clinic appointment with chemotherapy 150 Personal communication, Christie Hospital, Manchester, UK (2001)
Outpatient clinic appointment without chemotherapy 80 Personal communication, Christie Hospital, Manchester, UK (2001)
Medical oncology outpatient follow-up 88 NHS Reference costs (2001)
Day-case appointment 223 NHS Reference costs (2001)
District nurse home visit 20 Netten et al (2001)
GP home visit 60 Netten et al (2001)
GP telephone consultation 23 Netten et al (2001)
Day-care visit 129 Netten et al (2001)
GP surgery consultation 19 Netten et al (2001)
GP clinic consultation 27 Netten et al (2001)
A and E visit 62 Netten et al (2001)
Other hospital visits 76 Netten et al (2001)
Line insertion 509 Personal communication, Christie Hospital, Manchester, UK (2001)
Line insertion 549 Personal communication, Christie Hospital, Manchester, UK (adjusted)
Line insertion 265 Iveson et al (1999)
Pump 66 Iveson et al (1999)
Consultant hour 88 Netten et al (2001)
District nurse hour 44 Netten et al (2001)
Staff nurse hour 28 Netten et al (2001)
5-FU 1000mg vial 12.80 BNF no 43 (2002)
5-FU 5000mg vial 64.00 BNF no 43 (2002)
5-FU 500mg vial 6.40 BNF no 43 (2002)
5-FU 250mg vial 3.20 BNF no 43 (2002)
LV 50mg vial 19.41 BNF no 43 (2002)
LV 350mg vial 90.98 BNF no 43 (2002)
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sreview committee in the Hoff trial (25.8 vs 11.6%, P¼0.0001) and
the pooled data (22.4 vs 13.2%, Po0.0001) (Table 2). There was no
significant difference between the two groups in time to disease
progression or death, and time to treatment failure (Table 2).
There were no significant differences in duration of response or
survival between UFT/LV and 5-FU/LV in either trial (results not
shown). Time to disease progression was slightly inferior for the
UFT/LV group compared to the 5-FU/LV group in the Douillard
study (3.5 vs 3.8 months, P¼0.01; Table 2), although there was no
difference in time to disease progression between UFT/LV and 5-
FU/LV in the Carmichael study. Overall survival in the two groups
was also the same (Table 2).
Treatment with capecitabine had an improved adverse effect
profile in comparison with the Mayo regimen, with the exception
of hand-foot syndrome and hyperbilirubinaemia. UFT/LV was
associated with fewer adverse events than the 5-FU/LV regimen.
Neither capecitabine nor UFT/LV was associated with an
improvement in health-related quality of life.
Indirect comparison of infusional 5-FU regimens and oral
prodrugs
No direct trial evidence comparing oral drugs with infusional 5-FU
regimens was identified. A comparison of the Mayo regimen
against the infusional regimens was therefore undertaken. One
RCT was identified comparing the Mayo regimen to the de
Gramont regimen (de Gramont et al, 1997) along with other
supporting evidence (Meta-analysis Group in Cancer, 1998;
Cheeseman et al, 2002). The limited evidence base available
suggested that the de Gramont regimen may be superior to the
Mayo regimen in terms of progression-free survival and in relation
to toxicity, but that there was no statistically significant survival
benefit.
Cost analysis
A cost minimisation analysis was undertaken. The estimated total
treatment costs, based on a 12-week treatment period, are given in
Table 3. Detailed breakdown of the costs of administration and
adverse events are given in Tables 4–6. A sensitivity analysis on
total treatment costs using median treatment times in the trials was
also undertaken (Table 7).
The total treatment costs of both capecitabine and UFT/LV were
estimated to be lower than the treatment costs for the three
intravenous regimens. The cost estimates for UFT/LV, the Mayo
regimen and the MdG regimen were similar. The cost estimate for
de Gramont regimen is substantially higher than for the MdG
regimen, both in terms of drug costs and administration costs,
demonstrating the cost savings achieved over recent years by
adoption of MdG in the UK.
The sensitivity analysis showed that the cost estimates for
capecitabine were robust to changes in the cost parameters
(Table 7). Capecitabine offered cost savings relative to all three
intravenous therapies under all scenarios. The cost savings offered
by capecitabine were smallest in Scenario A in which an 87%
discount was applied to the cost of leucovorin (Table 7). This
discount reduced the cost of the intravenous regimens. In this
scenario, the cost difference between capecitabine and the MdG
regimen fell from d1353 in the basecase to d483. This scenario may
reflect the actual cost of lecovorin for many NHS institutions,
although the exact size of the discount received by individual
institutions is not known. UFT/LV costs remained lower than costs
for the intravenous regimens except in scenario D1 where
outpatient appointments with and without chemotherapy were
assumed to incur the same cost.
The impact of using median treatment times from the trials
(Table 7, scenario C) is to increase the estimated cost savings from
the oral chemotherapy drugs, except in the case of UFT/LV based
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son the Carmichael trial. In this trial, the median treatment time is 4
months for UFT/LV compared with 3.5 months for 5-FU and this
produces a slight cost saving in favour of the Mayo and MdG
regimens compared with UFT/LV.
DISCUSSION
This study shows that the higher drug cost of the oral
chemotherapy agents relative to conventional intravenous 5-FU
therapies are offset by lower administration costs, resulting in an
overall cost saving of oral therapies over intravenous therapies in
the UK.
Two previous economic evaluations were identified comparing
UFT/LV with 5-FU, based on the same South American study
(Murad et al, 1997a,b). Murad et al used a panel of six physicians
from Brazil and Argentina to estimate the costs of UFT/LV vs an
unspecified 5-FU regimen in each country, and found that UFT/LV
resulted in a small (d198 and d753) cost saving, mainly in the area
of adverse event management. More recently Maroun et al (2003)
provided a cost comparison of UFT/LV against Mayo regimen
5-FU from a Canadian perspective, based on a retrospective study
of the Canadian centres in the Carmichael and Douillard trials.
Hospital admission and oncology outpatient clinic visits were the
most significant cost drivers. The study found that patients on the
oral regimen had fewer outpatient visits for administration,
although this was partly offset by more days of hospitalisation
(reasons for hospitalisation were not given). Overall, cost savings
from UFT/LV (excluding drug costs) came to $Can3221 in 1996
values (d2013 in UK 2002 values) per patient over the entire course
of treatment.
Our study showed that oral chemotherapy drugs offer advan-
tages in relation to resource usage. Protracted infused regimens are
resource-intensive not only in terms of nurses and doctors to
administer the infusion but also in terms of pharmacy time and
resources. Drugs need to be prepared by specially trained
individuals in an isolated area. Although pharmacist time and
disposable bags, tubing, etc have been included in our cost
analysis, the use of oral drugs also offer the advantage of freeing up
time and space in isolated areas and allowing specialised
pharmacists to engage in other activities. It should be noted that
the use of dose banding has not been assumed in our calculations
and this will offer some savings for 5-FU chemotherapy. The
saving is unlikely to influence the findings of the paper.
As oral therapies can be prescribed and monitored through
outpatient appointments and outreach clinics, patients undergoing
oral treatment may have less contact with medical staff than those
undergoing intravenous therapies. While this has benefits of
savings to the health service and less travel and time required from
patients, there are also associated risks, especially of over-
compliance in the face of serious side effects. Owing to this,
patient selection and education are critical, and doctors and nurses
require training to carry out these tasks. Not all patients will be
suitable for oral therapies, as some may not be physically or
mentally capable. A good relationship is required between patients,
doctors and nurses to encourage patients to report their symptoms
accurately.
Evidence suggests that patients prefer oral therapies to
intravenous therapies, as long as efficacy is not compromised.
This was shown specifically by a crossover arm in a UFT/LV trial
(Borner et al, 2002), but has also been reported in other studies,
and was repeated by patient representatives advising the NICE
committee on guidance recommendations. It was suggested that
patients’ preference for oral therapies is based primarily on a
Table 3 Estimated total treatment costs (d2002)
Capecitabine UFT/LV Mayo MdG (outpatient) de Gramont (in-patient)
Drug cost 464 892 189 394 563
Administration 113 64 839 650 1500
Adverse events 131 170 170 29 22
Total 28-day costs 708 1126 1126 1073 2085
One-off costs 7 7 0 265 0
Total treatment costs (based on 12 week period) 2132 3385 3593 3485 6255
Cost savings on capecitabine  1461  1353  4123
Cost savings on UFT/LV  209  101  2870
Table 4 Cost of Administration (ds 2002)
Capecitabine UFT/LV Mayo MdG
de
Gramont
Cyclical expenses
Cost of outpatient visits 80 80 750 150
Pharmacy preparation 9 15 16
Nurse time 69 35
Pump 65
Community nurse visit 41
Administration disposables 11 20
Creatinine test 5
IP visits 734
Total cyclical admin costs 85 80 839 325 750
Weeks in cycle 3 5 4 2 2
28-day admin costs 113 64 839 650 1500
One-off expenses
Patient education Line
insertion
77
265
Table 5 Frequency of consultations and hospitalisations relating to
adverse events over treatment period for capecitabine, UFT/LV and Mayo
Capecitabine UFT/LV Mayo
Consultations
Day care visits 0.88 0.72
GP surgery visits 0.85 0.51 0.60
GP telephone consultations 0.55 0.43
A and E 0 .27
Clinic consultation 0.26
Other hospital visit 0.36
GP home visits 0.32 0.25
Hospitalisations
Hospital days 1.24 3.16 1.60
Sources: Capecitabine and Mayo regimens taken from Twelves et al (2001) and
Ollendorf (1999), UFT/LV taken from Roche (2002) and Pazdur et al (1999).
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and a greater feeling of control over management of their disease
(NICE, 2003).
Our analysis showed that drug administration costs were
sensitive to the cost of an outpatient appointment. Costs from
different sources vary widely. A similar finding was reported in the
Canadian study (Maroun et al, 2003), which also used a wide range
of values in a sensitivity analysis. It would be useful for a detailed
resource use study of chemotherapy appointments to be conducted
to determine the precise cost of OP appointments for intravenous
therapy compared with appointments for the prescription of oral
drugs.
Table 6 Cost of adverse events (ds 2002)
Capecitabine UFT Mayo MdG de Gramount
Consultations and hospitalisations 455 1162 586 139 139
Drug treatment of adverse events 41 17 153 33 33
Line complications 48
Total cost d656 d1240 d867 d220 d173
Cost per 28 day cycle d131 d326 d170 d29 d22
Sources: For capecitabine and Mayo regimens taken from Twelves et al, for UFT/LV taken from Roche (2002) and Pazdur et al (1999). For MdG and de Gramount taken from
Lloyd-Jones et al (2001) and Cheeseman et al (2002) except for line complications James R, Mid Kent Oncology Centre, Maidstone, personal communication, 2002).
Table 7 Results of sensitivity analysis (d2002)
(A) Capecitabine Capecitabine Mayo MdG de Gramont
Basecase
Costs d2132 d3593 d3485 d6255
Cost difference (Capecitabine minus 5-FU)  d1461  d1353  d4123
Sensitivity analysis
A: Price of leucovorin discounted by 87% d2132 d3296 d2615 d4852
 d1164  d483 -d2721
B: Drug costs based on mean dose intensities prescribed in trials d1867 d3536 d3485 d6255
 d1669  d1618 -d4388
C1: Treatment costs based on median treatment time from
Hoff et al (Capecitabine – 4.3months, 5-FU 4.6months)
d3316 d5985
 d2669
d5629
 d2313
d10419
 d7103
C2: Treatment costs based on median treatment time from
Van Cutsem et al (Capecitabine – 4.8months, 5-FU 4.6months)
d3700 d5985
 d2285
d5629
 d1928
d10419
 d6718
D1: OP appointments for oral chemotherpay and intravenou
chemotherapy assumed to have equal cost
d2258 d3015
 d757
d3254
 d996
d6255
 d3997
D2: OP appointments based on NHS reference costs d2164 d4687 d3923 d6255
 d2523  d1759  d4091
E: Adverse events costs excluded d1738 d3084 d3400 d6188
 d1346  d1662  d4450
(B) UFT/LV UFT/LV Mayo MdG de Gramont
Basecase
Costs d3385 d3593 d3485 d6255
Cost difference (UFT/LV minus 5-FU)  d209  d101  d2870
Sensitivity analysis
A: Price of leucovorin discounted by 87% d2504 d3296 d2615 d4852
 d792  d111  d2349
B: Drug costs based on mean dose intensities prescribed in trials d3197 d3536 d3485 d6255
 d339  d288  d3058
C1: Treatment costs based on median treatment time from
Douillard et al (UFT/LV 3.8months, 5-FU 3.8months)
d4655 d4944
 d289
d4696
 d41
d8607
 d3952
C2: Treatment costs based on median treatment time from
Carmichael et al (UFT/LV 4months, 5-FU 3.5months)
d4899 d4554
d345
d4346
d553
d7927
 d3028
D1: OP appointments for oral chemotherpay and intravenou
chemotherapy assumed to have equal cost
d3460 d3015
d445
d3254
d206
d6255
 d2795
D2: OP appointments based on NHS reference costs d3404 d4687 d3923 d6255
 d1283  d519  d2851
E: Adverse events costs excluded d2875 d3084 d3400 d6188
 d209  d524  d 3312
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LV treatment over treatment with 5-FU/LV(Borner et al, 2002).
Perhaps surprisingly, the improved side effect profile of oral
regimens when compared to the Mayo regimen, patient preference
for oral regimens, and improved response rates (for capecitabine)
did not translate into improved quality of life for patients on oral
therapies. This may reflect insensitivity of assessment tools, poor
compliance with assessments, or difficulties with timing of
questionnaire. However, it may also sound a note of caution:
perhaps the mild but chronic toxicities of oral therapy, although
never reaching an NCI CTC grade to cause alarm, may impact as
much or more on quality of life as the severe but short-lived
toxicities of cyclical intravenous drugs.
The greatest uncertainty in this analysis results from the
necessity to perform an indirect comparison of oral drugs with
the infusional 5-FU regimens. Further research comparing the
optimum infusional 5-FU regimens with oral drugs would allow
these treatments to be compared directly, in terms of efficacy,
toxicity and quality of life. Ongoing and planned projects are
making these comparisons in the context of combination therapy
including oxaliplatin, irinotecan or novel targeted agents. In
addition, the ongoing MRC FOCUS2 trial, in frail and elderly
patients, includes the first direct randomised comparison of MdG
vs capecitabine, with or without oxaliplatin.
In this study, we have shown that the higher cost of the oral
chemotherapy drugs for treatment of metastatic colorectal cancer
is offset by the lower cost of administration compared with
intravenous chemotherapy regimens. In the period since the
studies used in this analysis were conducted, the treatment of
colorectal cancer has moved on. In many countries, including the
UK, combination cytotoxic chemotherapy is a common option,
and attention is focussed on introduction of novel targeted drugs.
However, with oral-FP-based combination schedules the choices of
oral or intravenous fluoropyrimidines remain, and these issues
may in time extend to oral analogues of irinotecan and oxaliplatin.
The adoption of an oral chemotherapy regimen should of course
not be based on cost alone, but on the careful demonstration of at
least equivalent efficacy, with favourable toxicity and quality of life
for patients; however, the careful balancing, as here, of drug costs
and the associated costs of treatment should help doctors and
health commissioners in their goals to offer choices to patients
within the context of finite healthcare resources.
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